Hyderabad: On a day Union well being minister Mansukh Mandaviya reiterated the Indian authorities’s ‘zero tolerance’ coverage on spurious medicines by asking 18 firms to close store, Pharmexcil director normal R Uday Bhaskar mentioned although exports haven’t been impacted, the problem has dented India’s picture because the pharmacy of the world.
“WHO and regulators of various international locations are speaking about it and issuing public alerts. Whenever we have now interactions with regulators the primary level they need to talk about is on these points solely,” Bhaskar mentioned.
This was although cough syrups accounted for simply $15 million of India’s whole pharma exports of $25.4 billion in 2022-23 and 52 per cent of India’s pharma exports go to stringently regulated markets like Europe, the place exports recorded 15.5 per cent progress for the primary time, and US.
On India falling in need of the $27 billion goal, Bhaskar mentioned although exports grew solely 3.25 per cent in FY23 to $25.4 billion, Pharmexcil was gunning for $28 billion exports in 2023-24 because the US market, which has 31 per cent share of exports, has stablised, which is a constructive signal.
Despite international headwinds that led to unfavorable progress in key markets resembling Africa (-5 per cent) and CIS (-8 per cent) Indian pharma crossed the $25 billion mark for the primary time and grew 10.5 per cent in April 2023 alone, an optimistic Bhaskar mentioned whereas addressing mediapersons on the ninth version of Pharmexcil’s flagship International Pharma Exhibition to be held in Hyderabad from July 5 to 7. He mentioned IPHEX 2023 is a particular version being organised on the event of India’s G20 presidency and can embrace a G20 focussed CEOs roundtable of delegates from over 120 international locations.
